In a transformative shift within the biopharmaceutical manufacturing sector, Avid Bioservices, a premier biologics contract development and manufacturing organization (CDMO), has announced its agreement to be acquired by GHO Capital Partners and Ampersand Capital Partners for approximately $1.1 billion. This acquisition, valued at $12.50 per share, will take Avid Bioservices private, marking a major shift […]
Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635) has reported strong growth for the second quarter (Q2) and first half (H1) of the fiscal year 2024-2025. The company’s consolidated revenue for Q2 rose by 17% year-on-year (YoY) to ₹2,242 crore, supported by significant demand in its contract development and manufacturing organization (CDMO) business. Piramal also […]
Glenmark Life Sciences Limited (BSE: 543322, NSE: GLS), a prominent player in the pharmaceutical industry, has announced impressive financial results for the quarter ended June 30, 2024. The company’s revenue surged by 9.7% quarter-on-quarter (QoQ), reaching ₹5,886 million. This growth reflects a solid 1.8% increase year-on-year (YoY), underlining Glenmark Life Sciences’ strong performance amidst challenging […]
Global pharmaceutical giant, Lupin Limited, announced the appointment of Abdelaziz Toumi (commonly known as Abdel) as the Chief Executive Officer of its newly established subsidiary, Lupin Manufacturing Solutions (LMS). Based in Switzerland, Abdel brings a robust mix of scientific and commercial expertise to LMS, which is set to spearhead the development, manufacture, and sale of […]
Vetter, a leading global contract development and manufacturing organization (CDMO), has unveiled significant expansion plans, which include relocating and enlarging its Development Services site in the United States and launching a new commercial production facility in Germany. These strategic moves underscore Vetter’s commitment to increasing its capacity and presence on both continents amid growing outsourcing […]
In a strategic move that significantly escalates its capacity in the biologics manufacturing landscape, Lonza, a key global player in manufacturing for the pharmaceutical, biotech, and nutraceutical markets, announced its acquisition of Genentech’s large-scale biologics manufacturing facility in Vacaville, California, from Roche for USD 1.2 billion. This acquisition marks a significant expansion of Lonza’s manufacturing […]
Oxford Biomedica plc, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), is set to significantly enhance its global presence with the acquisition of ABL Europe SAS from Institut Mérieux. This strategic move, valued at €15 million, positions Oxford Biomedica as a key player in the biotechnology industry. This acquisition provides Oxford […]
Gland Pharma, an Indian contract development and manufacturing organization (CDMO), through its Singapore subsidiary Gland Pharma International, has agreed to acquire Cenexi, a French CDMO, at an enterprise value of €230 million. In this regard, the parties have signed a ‘Put Option Agreement’, which is expected to help Gland Pharma foray into the European CDMO […]
Jubilant Ingrevia, an Indian chemicals company, has bagged a contract development and manufacturing company (CDMO) contract with an estimated value of INR 270 crores for its specialty chemicals business. The contract is spread over a period of three years with an international customer, who is said to be among the top 10 innovator pharma companies […]
Windlas Biotech has cleared a GMP inspection of the European Union (EU) done by the National Institute of Pharmacy and Nutrition, Hungary for its plant-IV in Dehradun. The Indian domestic pharma formulations contract development and manufacturing organization (CDMO) said that there were zero critical observations reported by the licensing and administrative authority. Windlas Biotech had […]